Connect with us


Two day’s RSS meet begins on ‘love jihad’ in Prayagraj UP.



Public contributions for Ram Temple building and “love jihad” have been among the many matters mentioned at a Nationwide Govt Committee assembly of the Rashtriya Swayamsevak Sangh (RSS) that started Sunday in Prayagraj.

The very important meeting of the National Self-Service Association (RSS) is starting in Sangam city Prayagraj for two days from today. In this meeting of the four provinces of eastern Uttar Pradesh, all the key officials of the Sangh including Sir Sangh Chalak Mohan Bhagwat will participate. In the meeting, along with the participation of common people in Love Jihad, conversion and grand construction of Ram temple, many other important issues have to be discussed.

The 2-day assembly for the jap Uttar Pradesh area was attended by Chief Minister Yogi Adityanath together with Sir Sangh chalak Mohan Bhagwat and Sir karyawah Suresh “Bhaiyaji” Joshi, sources stated.

The minutes of the assembly weren’t launched. Sangh sources stated that in addition to outreach for contributions to Ram Temple building and “love jihad”, points similar to atmosphere conservation and the RSS’s function in village improvement for the Atma Nirbhar Bharat marketing campaign have been mentioned.

During the meeting, UP CM Yogi Adityanath is also expected to meet the RSS chief, although there is doubt about his arrival as the protocol is not yet in place. According to the information received from the sources, the Sangh is worried about the speed with which love jihad and conversion cases have increased in the country including eastern Uttar Pradesh. It is hoped that taking a major decision in this meeting of the Sangh regarding Love Jihad and conversion, the Central and State Governments can be advised to make a strict law in this regard and curb it strictly.

In the meeting, a decision can also be taken to increase the participation of the general public in the construction of a grand temple of Ram Lala in Ayodhya. All Ram devotees can be requested to participate directly through donations and other means.


447 cases of adverse effect reported,Covid-19 vaccine given to 2,24,301 beneficiaries :Govt.



A total of 2,24,301 beneficiaries have been inoculated with COVID-19 vaccine so far, out of which only 447 adverse events following immunisation (AEFI) were reported, the Union Health Ministry said on day two of the nationwide vaccination drive on Sunday.

Addressing a press briefing, the ministry’s Additional Secretary Manohar Agnani said out of the 447 adverse events following immunisation, only three required hospitalisation.

“Today being Sunday, only six states conducted vaccination drive and in 553 sessions a total of 17,072 beneficiaries were vaccinated,” he said.

The six states where the vaccination drive was carried out on Sunday are Andhra Pradesh, Arunachal Pradesh, Karnataka, Kerala, Manipur and Tamil Nadu, he added.

Agnani said a total of 2,24,301 beneficiaries have been vaccinated till January 17 as per provisional reports, adding that 2,07,229 of them received the jabs on day one of the drive.

“A total of 447 AEFI have been reported on January 16 and 17, out of which only three required hospitalisation. Most of the AEFI reported so far are minor like fever, headache, nausea,” he said.

He said a meeting was held with all states and union territories on Sunday to review the progress of the drive, identify bottlenecks and plan corrective actions.

Prime Minister Narendra Modi rolled out the world’s largest inoculation drive against COVID-19 on Saturday and said the two vaccines being deployed will ensure a “decisive victory” for India against the pandemic.

India has approved two vaccines—Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India—for emergency use in the country.

According to the government, the shots will be offered first to an estimated one crore healthcare workers and around two coror frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities. PTI

Continue Reading